Endo International (ENDP) Stock Rating Upgraded by Vetr

Endo International (NASDAQ:ENDP) (TSE:ENL) was upgraded by research analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday. The firm presently has a $8.92 price objective on the stock. Vetr‘s price target would indicate a potential upside of 13.63% from the company’s previous close.

A number of other research firms also recently weighed in on ENDP. Goldman Sachs Group initiated coverage on Endo International in a report on Thursday, September 28th. They set a “sell” rating and a $7.00 price objective on the stock. Royal Bank of Canada decreased their price objective on Endo International from $9.00 to $8.00 and set a “sector perform” rating on the stock in a report on Friday, November 10th. Guggenheim initiated coverage on Endo International in a report on Tuesday, December 12th. They set a “neutral” rating and a $8.50 price objective on the stock. Cantor Fitzgerald decreased their price objective on Endo International from $9.00 to $7.00 and set a “neutral” rating on the stock in a report on Friday, November 10th. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $9.00 price objective on shares of Endo International in a report on Sunday, September 17th. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $11.34.

Shares of Endo International (ENDP) opened at $7.85 on Tuesday. Endo International has a 1 year low of $5.77 and a 1 year high of $17.99. The firm has a market capitalization of $1,740.00, a PE ratio of -0.41, a P/E/G ratio of 2.13 and a beta of 0.59. The company has a debt-to-equity ratio of 10.78, a quick ratio of 0.86 and a current ratio of 1.08.

Endo International (NASDAQ:ENDP) (TSE:ENL) last released its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping analysts’ consensus estimates of $0.85 by $0.06. The business had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm’s revenue for the quarter was down 11.0% compared to the same quarter last year. During the same period last year, the business earned $1.01 earnings per share. analysts anticipate that Endo International will post 3.67 EPS for the current year.

A number of hedge funds have recently bought and sold shares of ENDP. Blair William & Co. IL bought a new position in Endo International in the 2nd quarter worth approximately $126,000. LMR Partners LLP bought a new position in Endo International in the 3rd quarter worth approximately $148,000. Riverhead Capital Management LLC raised its position in Endo International by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after purchasing an additional 5,887 shares during the last quarter. Bank of Hawaii bought a new position in Endo International in the 2nd quarter worth approximately $180,000. Finally, Flinton Capital Management LLC raised its position in Endo International by 64.4% in the 2nd quarter. Flinton Capital Management LLC now owns 20,400 shares of the company’s stock worth $228,000 after purchasing an additional 7,990 shares during the last quarter. Hedge funds and other institutional investors own 93.06% of the company’s stock.

WARNING: “Endo International (ENDP) Stock Rating Upgraded by Vetr” was first published by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.com-unik.info/2017/12/28/endo-international-endp-stock-rating-upgraded-by-vetr.html.

About Endo International

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International (NASDAQ:ENDP)

What are top analysts saying about Endo International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit